Andrew J. Armstrong

32.6k total citations · 6 hit papers
426 papers, 14.6k citations indexed

About

Andrew J. Armstrong is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andrew J. Armstrong has authored 426 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 371 papers in Pulmonary and Respiratory Medicine, 208 papers in Oncology and 151 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andrew J. Armstrong's work include Prostate Cancer Treatment and Research (328 papers), Radiopharmaceutical Chemistry and Applications (145 papers) and Cancer Immunotherapy and Biomarkers (70 papers). Andrew J. Armstrong is often cited by papers focused on Prostate Cancer Treatment and Research (328 papers), Radiopharmaceutical Chemistry and Applications (145 papers) and Cancer Immunotherapy and Biomarkers (70 papers). Andrew J. Armstrong collaborates with scholars based in United States, Canada and United Kingdom. Andrew J. Armstrong's co-authors include Ronald de Wit, Rhonda L. Bitting, Neal D. Shore, Daniel J. George, Johann S. de Bono, Fred Saad, Cora N. Sternberg, Howard I. Scher, Mario A. Eisenberger and Karim Fizazi and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Andrew J. Armstrong

403 papers receiving 14.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

2012 3.3k citations Karim Fizazi, Fred Saad et al. profile →
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

2019 686 citations Andrew J. Armstrong, Russell Z. Szmulewitz et al. Journal of Clinical Oncology profile →
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

2011 536 citations Andrew J. Armstrong, Matthew S. Marengo et al. Molecular Cancer Research profile →
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity

2014 393 citations Andrew J. Armstrong et al. European Urology profile →
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

2022 169 citations Andrew J. Armstrong, Russell Z. Szmulewitz et al. Journal of Clinical Oncology profile →
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

2023 132 citations Fred Saad, Neal D. Shore et al. profile →

Peers

Countries citing papers authored by Andrew J. Armstrong

Since Specialization

Citations

This map shows the geographic impact of Andrew J. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Armstrong more than expected).

Fields of papers citing papers by Andrew J. Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Armstrong. The network helps show where Andrew J. Armstrong may publish in the future.

Co-authorship network of co-authors of Andrew J. Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. Armstrong. A scholar is included among the top collaborators of Andrew J. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. Armstrong. Andrew J. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial 2024 ·Investigational New Drugs ·Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen, Jong Seok Lee, Frank Tsai, Benjamin Solomon, Tae Min Kim, Christian Rolfo, Vincent L. Giranda, Yixin Ren, Fang Liu, (unknown), Tomoko Freshwater, Judy S. Wang	33
2	Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial 2024 ·European Urology ·Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, (unknown), (unknown), Michael J. Morris	7
3	Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review 2024 ·European Urology ·Adam B. Weiner, (unknown), Andrew J. Armstrong, Alberto Bossi, Philip Cornford, Felix Y. Feng, Pratik Kanabur, R. Jeffery Karnes, Rana R. McKay, Todd M. Morgan, Edward M. Schaeffer, Neal D. Shore, Alison Tree, Daniel E. Spratt	13
4	The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 2024 ·Clinical Cancer Research ·Susan Halabi, (unknown), Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Donald P. McDonnell, John D. Norris, Changxue Lu, Jun Luo, Andrew J. Armstrong	8
5	Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey 2024 ·Prostate Cancer and Prostatic Diseases ·(unknown), Tanya B. Dorff, Alicia K. Morgans, Oliver Sartor, Neal D. Shore, Andrew J. Armstrong	5
6	264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) 2023 ·Annals of Oncology ·William Kevin Kelly, Daniel C. Danila, C-C. Lin, Jia-Lin Lee, Nobuaki Matsubara, Phil Ward, Andrew J. Armstrong, David Pook, (unknown), Tanya B. Dorff, Stefanie Fischer, (unknown), Lisa G. Horvath, Christopher Sumey, Zhi Yang, (unknown), Jamie N. Connarn, Hugo A. Penny, Julia Stieglmaier, Leonard J. Appleman	1
7	Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer 2023 ·The Journal of Pathology ·William Butler, Lingfan Xu, Yinglu Zhou, Qing Cheng, (unknown), Yiping He, (unknown), Zachary C. Hartman, Liang Cheng, Qing Yang, Mu‐En Wang, Ming Chen, Hong Zhang, Andrew J. Armstrong, Jiaoti Huang	10
8	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer 2022 ·Clinical Cancer Research ·Rahul Aggarwal, Alexander Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, Michael A. Carducci	18
9	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer 2021 ·Molecular Cancer Research ·Santosh Gupta, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, Andrew J. Armstrong	19
10	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer 2021 ·Clinical Cancer Research ·Catherine H. Marshall, Wei Fu, Hao Wang, Jong Chul Park, Theodore L. DeWeese, Phuoc T. Tran, Daniel Y. Song, (unknown), (unknown), (unknown), (unknown), (unknown), Nancy P. Moldawer, Pedro C. Barata, Charles G. Drake, Edwin M. Posadas, Andrew J. Armstrong, Oliver Sartor, Emmanuel S. Antonarakis	39
11	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma 2021 ·Clinical Cancer Research ·Andrew J. Armstrong, Andrew B. Nixon, (unknown), Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi	18
12	A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2) 2020 ·Clinical Cancer Research ·Stephen J. Freedland, (unknown), (unknown), Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, Edwin M. Posadas, (unknown), (unknown), Lauren E. Howard, Yuan Wu, Pao‐Hwa Lin	40
13	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer 2016 ·Clinical Cancer Research ·Santosh Gupta, Jing Li, Gabor Kemeny, Rhonda L. Bitting, (unknown), Jason A. Somarelli, Kathryn E. Ware, Simon G. Gregory, Andrew J. Armstrong	52
14	Development of a Novel c-MET–Based CTC Detection Platform 2016 ·Molecular Cancer Research ·Tian Zhang, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, Michael R. Harrison, David S. Hsu, Patrick Healy, Jing Li, (unknown), (unknown), Carey Hobbs, (unknown), Daniel J. George, Herbert I. Hurwitz, Mark C. Connelly, Mariano A. García-Blanco, Andrew J. Armstrong	36
15	Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Andrew J. Armstrong, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, J.‐E. Damber, Laurence Belkoff, Örjan Nordle, G. Forsberg, Michael A. Carducci, Роберто Пили	46
16	Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers breakdown → 2011 ·Molecular Cancer Research ·Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James Turnbull, Christina I. Herold, P. Kelly Marcom, Daniel J. George, Mariano A. García-Blanco	536
17	Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer 2011 ·Journal of Clinical Oncology ·Роберто Пили, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, (unknown), Anders Björk, Örjan Nordle, G. Forsberg, Michael A. Carducci, Andrew J. Armstrong	161
18	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer 2010 ·Clinical Cancer Research ·Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia Creel, Kelly Mundy, S. L. Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, Michael A. Carducci	62
19	Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer 2009 ·Clinical Cancer Research ·Andrew J. Armstrong, Elizabeth Garrett‐Mayer, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger	166
20	A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis 2007 ·Clinical Cancer Research ·Andrew J. Armstrong, Elizabeth Garrett‐Mayer, (unknown), Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger	282

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact